Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
Neonc Technologies, Inc.
Incyte Corporation
Yale University
H. Lee Moffitt Cancer Center and Research Institute
Xencor, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer Group Cologne
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
AbbVie
Bristol-Myers Squibb
Bristol-Myers Squibb
University Hospital Southampton NHS Foundation Trust